FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to dermatovenerology and may be used to treat the infections caused by human papilloma viruses, implemented through interleukin-18 induction. For this purpose, the inducer is presented by medicines of the peptide alloferon using the mechanical removal of any type of papilloma formation. The inducer is presented by injections of the preparation 'Allokin-alpha lyophilisate for solution for subcutaneous administration'; the therapeutic course is 3 injections every second day, and the course may be repeated. The inducter is presented by alloferon suppositories. The inducers are presented by the ointments containing alloferon.
EFFECT: method provides the effective treatment ensured by the stimulation of natural immunity through interleukin-18 induction.
4 cl, 3 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF COMPLEX THERAPY OF PRE-INVASIVE AND INVASIVE CERVICAL CANCER | 2013 |
|
RU2560689C2 |
| METHOD OF PRODUCING A DRUG BASED ON OLIGOPEPTIDE ALLOFERON-1, HAVING AN ANTIVIRAL AND IMMUNOMODULATING EFFECT, AND PROLONGED STORAGE MEDICINAL PRODUCT OBTAINED WITH ITS HELP | 2017 |
|
RU2737852C2 |
| MUCOSAL VACCINE FOR IMMUNE THERAPY OF DISEASES CAUSED BY HUMAN PAPILLOMA VIRUSES, AND RELATED THERAPY (VERSIONS) | 2008 |
|
RU2377305C1 |
| BIOLOGICALLY ACTIVE DERIVATIVES OF ALLOFERON-1 | 2013 |
|
RU2576830C2 |
| AGENT FOR EXTERNAL USE WITH ANTIVIRAL ACTION | 2021 |
|
RU2819719C2 |
| BIOLOGICALLY ACTIVE PEPTIDES | 2013 |
|
RU2575069C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING BIOLOGICALLY ACTIVE ALLOFERON AND ZINC COMPLEXES AND METHOD OF PRODUCTION THEREOF | 2019 |
|
RU2742565C1 |
| METHOD FOR ACTIVATION OF CYTOTOXIC LYMPHOCYTES | 2019 |
|
RU2751837C2 |
| BIOMARKER FOR PATIENT SELECTION AND RELATED METHODS | 2010 |
|
RU2552292C2 |
| COMBINATION OF POXVIRUS ENCODING HUMAN PAPILLOMA VIRUS POLYPEPTIDES, AND IL-2 WITH ANTI-PD-L1 ANTIBODY | 2020 |
|
RU2824962C1 |
